289 related articles for article (PubMed ID: 21364581)
1. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.
Sheng Q; Liu J
Br J Cancer; 2011 Apr; 104(8):1241-5. PubMed ID: 21364581
[TBL] [Abstract][Full Text] [Related]
2. EGFR/HER-targeted therapeutics in ovarian cancer.
Wilken JA; Badri T; Cross S; Raji R; Santin AD; Schwartz P; Branscum AJ; Baron AT; Sakhitab AI; Maihle NJ
Future Med Chem; 2012 Mar; 4(4):447-69. PubMed ID: 22416774
[TBL] [Abstract][Full Text] [Related]
3. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract][Full Text] [Related]
4. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
5. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
6. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ
J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028
[TBL] [Abstract][Full Text] [Related]
7. ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
Anderson NG; Ahmad T
Front Biosci; 2002 Sep; 7():d1926-40. PubMed ID: 12161338
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells.
Lammering G; Lin PS; Contessa JN; Hampton JL; Valerie K; Schmidt-Ullrich RK
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):775-84. PubMed ID: 11697324
[TBL] [Abstract][Full Text] [Related]
9. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
10. Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
Pellat A; Vaquero J; Fouassier L
Hepatology; 2018 Feb; 67(2):762-773. PubMed ID: 28671339
[TBL] [Abstract][Full Text] [Related]
11. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
[TBL] [Abstract][Full Text] [Related]
12. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
[TBL] [Abstract][Full Text] [Related]
13. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
[TBL] [Abstract][Full Text] [Related]
14. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.
Reddy TP; Choi DS; Anselme AC; Qian W; Chen W; Lantto J; Horak ID; Kragh M; Chang JC; Rosato RR
Breast Cancer Res; 2020 May; 22(1):48. PubMed ID: 32414394
[TBL] [Abstract][Full Text] [Related]
16. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
Kiavue N; Cabel L; Melaabi S; Bataillon G; Callens C; Lerebours F; Pierga JY; Bidard FC
Oncogene; 2020 Jan; 39(3):487-502. PubMed ID: 31519989
[TBL] [Abstract][Full Text] [Related]
17. EGFR family: structure physiology signalling and therapeutic targets.
Burgess AW
Growth Factors; 2008 Oct; 26(5):263-74. PubMed ID: 18800267
[TBL] [Abstract][Full Text] [Related]
18. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.
Claus J; Patel G; Ng T; Parker PJ
Biochem Soc Trans; 2014 Aug; 42(4):831-6. PubMed ID: 25109965
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
20. ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
Song X; Fan PD; Bantikassegn A; Guha U; Threadgill DW; Varmus H; Politi K
Cancer Res; 2015 Mar; 75(6):1035-45. PubMed ID: 25596284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
